These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 36169959

  • 21. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.
    Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Chen C, Parks B, Miller C.
    Ther Adv Neurol Disord; 2020; 13():1756286420915005. PubMed ID: 32426039
    [Abstract] [Full Text] [Related]

  • 22. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
    Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW, European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators.
    Neurology; 2002 Nov 26; 59(10):1507-17. PubMed ID: 12451189
    [Abstract] [Full Text] [Related]

  • 23. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, Meka V, Okwuokenye M, Hotermans C, Mendoza JP, Mann MK, Meltzer LA.
    Mult Scler Relat Disord; 2018 May 26; 22():27-34. PubMed ID: 29524759
    [Abstract] [Full Text] [Related]

  • 24. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J.
    N Engl J Med; 2015 Oct 08; 373(15):1418-28. PubMed ID: 26444729
    [Abstract] [Full Text] [Related]

  • 25. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S, Rahimi R, Abdollahi M.
    Clin Ther; 2010 Oct 08; 32(11):1871-88. PubMed ID: 21095482
    [Abstract] [Full Text] [Related]

  • 26. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
    Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, BRAVO Study Group.
    J Neurol; 2014 Apr 08; 261(4):773-83. PubMed ID: 24535134
    [Abstract] [Full Text] [Related]

  • 27. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P, CHAMPS.
    Clin Ther; 2003 Nov 08; 25(11):2865-74. PubMed ID: 14693310
    [Abstract] [Full Text] [Related]

  • 28. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
    Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM.
    Neurology; 2009 Jun 09; 72(23):1989-93. PubMed ID: 19506220
    [Abstract] [Full Text] [Related]

  • 29. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
    Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
    Neurology; 2012 Apr 03; 78(14):1069-78. PubMed ID: 22442431
    [Abstract] [Full Text] [Related]

  • 30. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
    Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy, University of British Columbia MS/MRI Research Group.
    Neurology; 2002 Nov 26; 59(10):1496-506. PubMed ID: 12451188
    [Abstract] [Full Text] [Related]

  • 31. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
    Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL.
    JAMA Neurol; 2020 Sep 01; 77(9):1132-1140. PubMed ID: 32511687
    [Abstract] [Full Text] [Related]

  • 32. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R, Ghazi-Visser L, Martins Silva A, Arvanitis M, Kuusisto H, Marhardt K, Vlaikidis N, STAR Study Group.
    Clin Ther; 2014 Dec 01; 36(12):1946-1957. PubMed ID: 24811754
    [Abstract] [Full Text] [Related]

  • 33. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Mokliatchouk O, Jiang X, Lyons J, Kapadia S, Miller C.
    Mult Scler; 2022 Apr 01; 28(5):801-816. PubMed ID: 34465252
    [Abstract] [Full Text] [Related]

  • 34. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A.
    BMC Neurol; 2018 Sep 14; 18(1):143. PubMed ID: 30217172
    [Abstract] [Full Text] [Related]

  • 35. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
    Jožef M, Locatelli I, Brecl Jakob G, Rot U, Kos M.
    Mult Scler Relat Disord; 2023 Apr 14; 72():104615. PubMed ID: 36933300
    [Abstract] [Full Text] [Related]

  • 36. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G.
    Contemp Clin Trials; 2015 Mar 14; 41():69-74. PubMed ID: 25545026
    [Abstract] [Full Text] [Related]

  • 37. Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study.
    Højsgaard Chow H, Talbot J, Lundell H, Marstrand L, Gøbel Madsen C, Bach Søndergaard H, Bredahl Hansen M, Solberg Sørensen P, Siebner HR, Sellebjerg F.
    Mult Scler Relat Disord; 2023 Feb 14; 70():104458. PubMed ID: 36586351
    [Abstract] [Full Text] [Related]

  • 38. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS, EVOLVE-MS-2 Study Group.
    CNS Drugs; 2020 Feb 14; 34(2):185-196. PubMed ID: 31953790
    [Abstract] [Full Text] [Related]

  • 39. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug 14; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

  • 40. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T, Kira J, Ueno Y, Harada N, Hirakata T.
    Mult Scler Relat Disord; 2016 May 14; 7():102-8. PubMed ID: 27237769
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.